Gilad Oren, the President and CEO of Aprea Therapeutics, Inc. (NASDAQ:APRE), recently acquired 500 shares of common stock in the company. The purchase, valued at approximately $1,957, was executed at a weighted average price of $3.915 per share, with transaction prices ranging from $3.91 to $3.92. Following this acquisition, Oren holds a total of 333,395 shares directly. Additionally, he has indirect ownership of 1,800 shares through his children, with 1,200 shares attributed to his daughter and 600 shares to his son. Oren disclaims beneficial ownership of the indirectly held shares.
In other recent news, Aprea Therapeutics has reported preliminary safety results from its ongoing Phase 1 trial, ACESOT-1051, which evaluates the new cancer drug APR-1051. The trial's early findings, presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, showed that the drug is safe and well-tolerated, with no hematologic toxicity observed. The study is currently in the dose escalation phase, and the reported adverse events were of low grades with no signs of neutropenia. Philippe Pultar, MD, Senior Medical Advisor and Lead of WEE1 Clinical Development at Aprea, expressed optimism about the drug's safety profile. The trial, which is active at three locations in the U.S., is expected to provide further efficacy data by 2025. Aprea's lead program is ATRN-119, an ATR inhibitor in development for solid tumor indications. APR-1051 has recently entered clinical trials. These are among the recent developments in the company.
InvestingPro Insights
To provide additional context to Gilad Oren's recent stock purchase, let's examine some key financial metrics and insights from InvestingPro.
Aprea Therapeutics currently has a market capitalization of $21.18 million, reflecting its status as a small-cap biotech company. Despite the CEO's recent share acquisition, which might signal confidence in the company's prospects, InvestingPro Tips indicate that Aprea is "quickly burning through cash" and "not profitable over the last twelve months." This aligns with the company's negative gross profit of -$7.05 million for the last twelve months as of Q2 2023.
On a positive note, an InvestingPro Tip highlights that Aprea "holds more cash than debt on its balance sheet," which could provide some financial flexibility as the company navigates its development stage. Additionally, the stock has shown a "strong return over the last month," with a 30.87% price total return, potentially reflecting market optimism or speculative interest.
However, investors should be aware that Aprea's stock "price movements are quite volatile," which is typical for early-stage biotech companies. The company's price-to-book ratio of 0.83 suggests that the stock is trading below its book value, which could be of interest to value-oriented investors.
For those seeking a more comprehensive analysis, InvestingPro offers 10 additional tips for Aprea Therapeutics, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.